This drug selectively inhibits vascular endothelial growth factor receptors to block tumor angiogenesis, and has demonstrated significant improvement in progression-free survival in Phase III clinical trials. 该药物通过选择性抑制血管内皮生长因子受体来阻断肿瘤血管生成,已在III期临床试验中显示出显著的无进展生存期改善。